(Circulation. 2001;103:1869.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Elevated Urinary Albumin Excretion Is Associated With Impaired Arterial Dilatory Capacity in Clinically Healthy Subjects
From the Department of Nephrology and Endocrinology, State University Hospital, Copenhagen (P.C., B.F.-R.), and the Copenhagen City Heart Study, Epidemiological Research Unit, Bispebjerg Municipal Hospital, the University of Copenhagen (J.S.J., G.J., K.B.-J.), Denmark.
Correspondence to Peter Clausen, MD, PhD, Department P 2131, Nephrology and Endocrinology, State University Hospital, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark. E-mail pclausen{at}rh.dk
Background—Elevated urinary albumin excretion (UAE) predicts atherosclerotic cardiovascular disease. It is hypothesized that elevated UAE is associated with a generalized vascular dysfunction. This study tested this hypothesis for conduit arteries.
Methods and Results—Clinically healthy subjects were selected: 19 with UAE >90th percentile in the background population (6.6 µg/min<UAE<150 µg/min) and 41 with normoalbuminuria (UAE <6.6 µg/min). External ultrasound was used to measure the dilatory response of the brachial artery to postischemic increased blood flow (endothelium-dependent, flow-associated dilation) and to nitroglycerin (endothelium-independent, nitroglycerin-induced dilation). Plasma concentrations of the endothelial markers nitrate/nitrite, thrombomodulin, and von Willebrand factor antigen were also measured. Both flow-associated and nitroglycerin-induced dilations were significantly impaired in subjects with elevated UAE as compared with normoalbuminuric control subjects: 102.0±1.0% (mean±SEM) versus 104.3±0.6% (P<0.05) and 120.1±1.5% versus 123.8±1.0% (P<0.05). No differences in the plasma concentrations of endothelial markers were found.
Conclusions—Slightly elevated UAE is associated with impaired conduit arterial dilatory capacity in clinically healthy subjects, and this impairment may be explained by a reduced dilatory response to nitric oxide of both endogenous and exogenous origin. Impaired arterial dilatory capacity may contribute to the increased cardiovascular risk in subjects with elevated UAE.
Key Words: atherosclerosis • risk factors • endothelium • vasodilation • nitric oxide • nitroglycerin
This article has been cited by other articles:
 |
|
 |
|
  M. Hornum, P. Clausen, J. Kjaergaard, J. M. Hansen, E. R. Mathiesen, and B. Feldt-Rasmussen Pre-diabetes and arterial stiffness in uraemic patients Nephrol. Dial. Transplant., October 21, 2009; (2009) gfp558v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Agarwal and R. P. Light GFR, proteinuria and circadian blood pressure Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2400 - 2406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bohm, M. Thoenes, H.-R. Neuberger, S. Graber, J.-C. Reil, P. Bramlage, and M. Volpe Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients Eur. Heart J., June 1, 2009; 30(11): 1364 - 1371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Anderson, J. B. Halter, W. R. Hazzard, J. Himmelfarb, F. M. Horne, G. A. Kaysen, J. W. Kusek, S. G. Nayfield, K. Schmader, Y. Tian, et al. Prediction, Progression, and Outcomes of Chronic Kidney Disease in Older Adults J. Am. Soc. Nephrol., June 1, 2009; 20(6): 1199 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Forman, N. D.L. Fisher, E. L. Schopick, and G. C. Curhan Higher Levels of Albuminuria within the Normal Range Predict Incident Hypertension J. Am. Soc. Nephrol., October 1, 2008; 19(10): 1983 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Schneider, E. Ferrannini, R. DeFronzo, G. Schernthaner, J. Yates, and E. Erdmann Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease J. Am. Soc. Nephrol., January 1, 2008; 19(1): 182 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Wang, P. Gona, M. G. Larson, D. Levy, E. J. Benjamin, G. H. Tofler, P. F. Jacques, J. B. Meigs, N. Rifai, J. Selhub, et al. Multiple Biomarkers and the Risk of Incident Hypertension Hypertension, March 1, 2007; 49(3): 432 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Brosius III, T. H. Hostetter, E. Kelepouris, M. M. Mitsnefes, S. M. Moe, M. A. Moore, S. Pennathur, G. L. Smith, and P. W.F. Wilson REPRINT Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease: A Science Advisory From the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developed in Collaboration With the National Kidney Foundation Hypertension, October 1, 2006; 48(4): 751 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Brosius III, T. H. Hostetter, E. Kelepouris, M. M. Mitsnefes, S. M. Moe, M. A. Moore, S. Pennathur, G. L. Smith, and P. W.F. Wilson Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease: A Science Advisory From the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developed in Collaboration With the National Kidney Foundation Circulation, September 5, 2006; 114(10): 1083 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tonelli, N. Wiebe, B. Culleton, A. House, C. Rabbat, M. Fok, F. McAlister, and A. X. Garg Chronic Kidney Disease and Mortality Risk: A Systematic Review J. Am. Soc. Nephrol., July 1, 2006; 17(7): 2034 - 2047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tonelli, P. Jose, G. Curhan, F. Sacks, E. Braunwald, M. Pfeffer, and Cholesterol and Recurrent Events (CARE) Trial Inve Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial BMJ, June 17, 2006; 332(7555): 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kathiresan, P. Gona, M. G. Larson, J. A. Vita, G. F. Mitchell, G. H. Tofler, D. Levy, C. Newton-Cheh, T. J. Wang, E. J. Benjamin, et al. Cross-Sectional Relations of Multiple Biomarkers From Distinct Biological Pathways to Brachial Artery Endothelial Function Circulation, February 21, 2006; 113(7): 938 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sonmez, A. O. Eskisar, D. Demir, M. V. Yazicioglu, B. Mutlu, Y. Dogan, A. Izgi, D. Mansuroglu, R. B. Bakal, O. H. Elonu, et al. Increased Urinary Albumin Excretion Rates Can Be a Marker of Coexisting Coronary Artery Disease in Patients with Peripheral Arterial Disease Angiology, January 1, 2006; 57(1): 15 - 20. [Abstract] [PDF]
|
|
|
|
|
|
G. L. Bakris, V. Fonseca, R. E. Katholi, J. B. McGill, F. Messerli, R. A. Phillips, P. Raskin, J. T. Wright Jr, B. Waterhouse, M. A. Lukas, et al. Differential Effects of {beta}-Blockers on Albuminuria in Patients With Type 2 Diabetes Hypertension, December 1, 2005; 46(6): 1309 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Gupta, R. A. Parker, G. K. Robbins, M. P. Dube, and for the Adult AIDS Clinical Trials Group 384 A5005 The effects of highly active antiretroviral therapy on albuminuria in HIV-infected persons: results from a randomized trial Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2237 - 2242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bakris Proteinuria: A Link to Understanding Changes in Vascular Compliance? Hypertension, September 1, 2005; 46(3): 473 - 474. [Full Text] [PDF]
|
|
|
|
|
|
J. Arnlov, J. C. Evans, J. B. Meigs, T. J. Wang, C. S. Fox, D. Levy, E. J. Benjamin, R. B. D'Agostino, and R. S. Vasan Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study Circulation, August 16, 2005; 112(7): 969 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Tuttle Renal manifestations of the metabolic syndrome Nephrol. Dial. Transplant., May 1, 2005; 20(5): 861 - 864. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Wang, J. C. Evans, J. B. Meigs, N. Rifai, C. S. Fox, R. B. D'Agostino, D. Levy, and R. S. Vasan Low-Grade Albuminuria and the Risks of Hypertension and Blood Pressure Progression Circulation, March 22, 2005; 111(11): 1370 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ibsen, M. H. Olsen, K. Wachtell, K. Borch-Johnsen, L. H. Lindholm, C. E. Mogensen, B. Dahlof, R. B. Devereux, U. de Faire, F. Fyhrquist, et al. Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study Hypertension, February 1, 2005; 45(2): 198 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pedrinelli, G. Dell'Omo, V. Di Bello, G. Pellegrini, L. Pucci, S. Del Prato, and G. Penno Low-Grade Inflammation and Microalbuminuria in Hypertension Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2414 - 2419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Clapp, A. D. Hingorani, R. K. Kharbanda, V. Mohamed-Ali, J. W. Stephens, P. Vallance, and R. J. MacAllister Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress Cardiovasc Res, October 1, 2004; 64(1): 172 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Endemann and E. L. Schiffrin Endothelial Dysfunction J. Am. Soc. Nephrol., August 1, 2004; 15(8): 1983 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. A. Stehouwer Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease Nephrol. Dial. Transplant., April 1, 2004; 19(4): 778 - 781. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension, November 1, 2003; 42(5): 1050 - 1065. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation, October 28, 2003; 108(17): 2154 - 2169. [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Liu, D. C. Robbins, V. Palmieri, J. N. Bella, M. J. Roman, R. Fabsitz, B. V. Howard, T. K. Welty, E. T. Lee, and R. B. Devereux Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: The Strong Heart Study J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2022 - 2028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rossing, P. K. Christensen, S. Andersen, P. Hovind, H. P. Hansen, and H.-H. Parving Comparative Effects of Irbesartan on Ambulatory and Office Blood Pressure: A substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Diabetes Care, March 1, 2003; 26(3): 569 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chelliah, G. A. Sagnella, N. D. Markandu, and G. A. MacGregor Urinary Protein and Essential Hypertension in Black and in White People Hypertension, June 1, 2002; 39(6): 1064 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P Garg and G. L Bakris Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease Vascular Medicine, February 1, 2002; 7(1): 35 - 43. [Abstract] [PDF]
|
|
|
|
|
|
R. Pedrinelli, G. Dell'Omo, G. Penno, and M. Mariani Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease Vascular Medicine, November 1, 2001; 6(4): 257 - 264. [Abstract] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Diabetes and Hypertension Diabetes Care, September 1, 2001; 24(9): 1679 - 1684. [Full Text] [PDF]
|
|